Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

被引：7

作者：

Coulter, Jonathan B. ^{[1
]}

Easwaran, Hariharan ^{[2
]}

机构：

[1] Johns Hopkins Univ, Brady Urol Inst, Sch Med, Baltimore, MD USA

[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Genet & Epigenet, Oncol,Sch Med, Baltimore, MD 21231 USA

来源：

PLOS BIOLOGY | 2023年 / 21卷 / 04期

关键词：

POLYCOMB;

D O I：

10.1371/journal.pbio.3002081

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

引用

页数：4

共 50 条

[31] The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells [J].

Shin, Yong Jae ;

Kim, Jeong-Ho .

PLOS ONE, 2012, 7 (01)

[32] Chromatin accessibility analysis reveals distinct functions for HDAC and EZH2 activities in early appendage regeneration [J].

Arbach, Hannah E. ;

Harland-Dunaway, Marcus ;

Braden, Christopher ;

Chitsazan, Alexander D. ;

Pickering, Eleanor ;

Patel, Jeet H. ;

Wills, Andrea E. .

WOUND REPAIR AND REGENERATION, 2022, 30 (06) :707-725

[33] Regulation of EZH2 Expression by INPP4B in Normal Prostate and Primary Prostate Cancer [J].

Zhang, Manqi ;

Ceyhan, Yasemin ;

Mei, Shenglin ;

Hirz, Taghreed ;

Sykes, David B. ;

Agoulnik, Irina U. .

CANCERS, 2023, 15 (22)

[34] The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells [J].

Miele, Evelina ;

Valente, Sergio ;

Alfano, Vincenzo ;

Silvano, Marianna ;

Mellini, Paolo ;

Borovika, Diana ;

Marrocco, Biagina ;

Po, Agnese ;

Besharat, Zein Mersini ;

Catanzaro, Giuseppina ;

Battaglia, Giuseppe ;

Abballe, Luana ;

Zwergel, Clemens ;

Stazi, Giulia ;

Milite, Ciro ;

Castellano, Sabrina ;

Tafani, Marco ;

Trapencieris, Peteris ;

Mai, Antonello ;

Ferretti, Elisabetta .

ONCOTARGET, 2017, 8 (40) :68557-68570

[35] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].

Bitler, Benjamin G. ;

Aird, Katherine M. ;

Garipov, Azat ;

Li, Hua ;

Amatangelo, Michael ;

Kossenkov, Andrew V. ;

Schultz, David C. ;

Liu, Qin ;

Shih, Ie-Ming ;

Conejo-Garcia, Jose R. ;

Speicher, David W. ;

Zhang, Rugang .

NATURE MEDICINE, 2015, 21 (03) :231-+

[36] Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma [J].

Wang, Zhengshi ;

Dai, Jiaqi ;

Yan, Jie ;

Zhang, Yun ;

Yin, Zhiqiang .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (07) :4770-4778

[37] SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways [J].

Yuan, Huairui ;

Han, Ying ;

Wang, Xuege ;

Li, Ni ;

Liu, Qiuli ;

Yin, Yuye ;

Wang, Hanling ;

Pan, Lulu ;

Li, Li ;

Song, Kun ;

Qiu, Tong ;

Pan, Qiang ;

Chen, Qilong ;

Zhang, Guoying ;

Zang, Yi ;

Tan, Minjia ;

Zhang, Jian ;

Li, Qintong ;

Wang, Xiaoming ;

Jiang, Jun ;

Qin, Jun .

CANCER CELL, 2020, 38 (03) :350-+

[38] The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type [J].

Wang, Yemin ;

Chen, Shary Yuting ;

Karnezis, Anthony N. ;

Colborne, Shane ;

Dos Santos, Nancy ;

Lang, Jessica D. ;

Hendricks, William P. D. ;

Orlando, Krystal A. ;

Yap, Damian ;

Kommoss, Friedrich ;

Bally, Marcel B. ;

Morin, Gregg B. ;

Trent, Jeffrey M. ;

Weissman, Bernard E. ;

Huntsman, David G. .

JOURNAL OF PATHOLOGY, 2017, 242 (03) :371-383

[39] SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 [J].

Kim, Kimberly H. ;

Kim, Woojin ;

Howard, Thomas P. ;

Vazquez, Francisca ;

Tsherniak, Aviad ;

Wu, Jennifer N. ;

Wang, Weishan ;

Haswell, Jeffrey R. ;

Walensky, Loren D. ;

Hahn, William C. ;

Orkin, Stuart H. ;

Roberts, Charles W. M. .

NATURE MEDICINE, 2015, 21 (12) :1491-+

[40] Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer [J].

Kwon, Daniel H. ;

Zhang, Li ;

Quigley, David A. ;

Foye, Adam ;

Chen, William S. ;

Wong, Christopher K. ;

Feng, Felix Y. ;

Bailey, Adina ;

Huang, Jiaoti ;

Stuart, Joshua M. ;

Friedl, Verena ;

Weinstein, Alana S. ;

Beer, Tomasz M. ;

Alumkal, Joshi J. ;

Rettig, Matthew ;

Gleave, Martin ;

Lara, Primo N., Jr. ;

Thomas, George V. ;

Li, Patricia ;

Lui, Austin ;

Small, Eric J. ;

Aggarwal, Rahul R. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) :931.e9-931.e16

← 1 2 3 4 5 →